Last reviewed · How we verify

ABBV-932 — Competitive Intelligence Brief

ABBV-932 (ABBV-932) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody, T-cell engager. Area: Oncology.

phase 2 Bispecific antibody, T-cell engager CD3 and tumor-associated antigen (specific target not publicly disclosed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABBV-932 (ABBV-932) — AbbVie. ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABBV-932 TARGET ABBV-932 AbbVie phase 2 Bispecific antibody, T-cell engager CD3 and tumor-associated antigen (specific target not publicly disclosed)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody, T-cell engager class)

  1. AbbVie · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABBV-932 — Competitive Intelligence Brief. https://druglandscape.com/ci/abbv-932. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: